Astex initiates phase 2 liver cancer trials

Hannah Blake


Astex Pharmaceuticals has initiated phase 2, open-label, single-arm, clinical trials evaluating SGI-110 in the treatment of advanced hepatocellular carcinoma (HCC) patients who failed prior treatment with Nexavar (sorafenib).

Advanced hepatocellular carcinoma (HCC) is the most common primary malignant tumor of the liver. HCC is a disease with a very high unmet medical need and patients who do not respond to the frontline standard of care, sorafenib, have few therapeutic options.

“There is a high unmet need for therapies for advanced HCC patients who have failed sorafenib treatment. We are pleased to initiate this study which expands the investigational breadth of our development program for SGI-110 to include HCC in addition to the ongoing studies in myelodysplastic syndromes (MDS), acute myeloid leukemia (AML) and ovarian cancer.”

Mohammad Azab, MD, chief medical officer, Astex.

Astex’s Phase 2 study is based on preclinical work showing that SGI-110 is effective in inducing global DNA and gene specific hypomethylation, thus enabling the re-expression of tumor suppressor genes in HCC cell lines.




Related news:

Astex starts mid-stage liver cancer trial (San Francisco Business Times)

Reference links:

Astex Pharmaceuticals press release

Don't miss your daily pharmaphorum news.
SUBSCRIBE free here.